AMS vs. TSTL, BMK, MXCT, NIOX, PRTC, BVXP, UPR, OXB, HVO, and APH
Should you be buying Advanced Medical Solutions Group stock or one of its competitors? The main competitors of Advanced Medical Solutions Group include Tristel (TSTL), Benchmark (BMK), MaxCyte (MXCT), NIOX Group (NIOX), PureTech Health (PRTC), Bioventix (BVXP), Uniphar (UPR), Oxford Biomedica (OXB), hVIVO (HVO), and Alliance Pharma (APH). These companies are all part of the "medical" sector.
Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Advanced Medical Solutions Group pays an annual dividend of GBX 2 per share and has a dividend yield of 1.0%. Tristel pays an annual dividend of GBX 13 per share and has a dividend yield of 2.8%. Advanced Medical Solutions Group pays out 2,857.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
In the previous week, Advanced Medical Solutions Group's average media sentiment score of 1.86 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.
Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Advanced Medical Solutions Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.
Tristel has a net margin of 15.29% compared to Advanced Medical Solutions Group's net margin of 12.59%. Tristel's return on equity of 20.35% beat Advanced Medical Solutions Group's return on equity.
66.9% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 50.3% of Tristel shares are owned by institutional investors. 2.6% of Advanced Medical Solutions Group shares are owned by insiders. Comparatively, 5.4% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Advanced Medical Solutions Group has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Tristel has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.
Advanced Medical Solutions Group presently has a consensus price target of GBX 300, indicating a potential upside of 55.44%. Tristel has a consensus price target of GBX 390, indicating a potential downside of 15.68%. Given Advanced Medical Solutions Group's higher possible upside, equities analysts clearly believe Advanced Medical Solutions Group is more favorable than Tristel.
Advanced Medical Solutions Group received 16 more outperform votes than Tristel when rated by MarketBeat users. However, 57.36% of users gave Tristel an outperform vote while only 49.70% of users gave Advanced Medical Solutions Group an outperform vote.
Summary
Tristel beats Advanced Medical Solutions Group on 9 of the 17 factors compared between the two stocks.
Get Advanced Medical Solutions Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Advanced Medical Solutions Group Competitors List
Related Companies and Tools
